Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The factors included a decline in advertising and promotional expenses associated with the launch of “Tansa fatty acid” in the same quarter of the previous year, greater efficiency in promotional activities, and a lower expense burden from upfront investments, including research and development expenses, made in the previous fiscal year to strengthen evidence. In terms of sales, growth was supported by the solid performance of “Bifina®” in Asia, inbound demand in Japan, sales of flavor capsules, and new adoptions by major manufacturers.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 3,476 million yen (YoY +4.0%) |
| Operating profit | 417 million yen (YoY +115.0%) |
| Ordinary income | 436 million yen (YoY +108.5%) |
| Profit attributable to owners of the parent | 324 million yen (YoY +99.1%) |
| Net income per share | ¥79.24 |
| Equity ratio | End of the current fiscal period 69.6 / End of previous period 69.7 |
| Total assets | 18,620 million yen |
| Net assets | 12,967 million yen |
| Full-year earnings forecast | Net Sales 12,400 million yen (YoY -2.3%) / Operating profit 650 million yen (YoY -6.1%) / Ordinary income 700 million yen (YoY -9.5%) / Net income 530 million yen (YoY -15.7%) |
| Revision to Earnings Forecast | Second quarter (cumulative) Net Sales 6,300 / Operating profit 330 / Ordinary income 370 / Net income 270 / Full year Net Sales 12,400 / Operating profit 650 / Ordinary income 700 / Net income 530 → Second quarter (cumulative) Net Sales 6,300 / Operating profit 330 / Ordinary income 370 / Net income 270 / Full year Net Sales 12,400 / Operating profit 650 / Ordinary income 700 / Net income 530（None） |
| Annual Dividend Forecast | 65 yen → 65 yen（0.0%） |
| Segment revenue | Consumer Business 1,260 million yen (YoY +6.8%), Solutions Business 2,214 million yen (YoY +2.5%), Other 1 million yen (YoY -17.6%) |
| Segment profit | Consumer Business 128 million yen, Solutions Business 290 million yen (YoY +27.9%), Other -2 million yen |
| Depreciation and amortization | 168 million yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No (no companies newly consolidated or excluded) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 4,150,000 Shares |
| Treasury Shares at Period-End | 51,275 Shares |
| Factors Behind Changes in Business Performance | The factors included a decline in advertising and promotional expenses associated with the launch of “Tansa fatty acid” in the same quarter of the previous year, greater efficiency in promotional activities, and a lower expense burden from upfront investments, including research and development expenses, made in the previous fiscal year to strengthen evidence. In terms of sales, growth was supported by the solid performance of “Bifina®” in Asia, inbound demand in Japan, sales of flavor capsules, and new adoptions by major manufacturers. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Consumer Business, advertising and promotional expenses associated with the launch of “Tansa fatty acid” in the same period of the previous year declined, and promotional activities became more efficient. In the Solutions Business, the expense burden from upfront investments, including research and development expenses, made in the previous fiscal year to strengthen evidence declined.